PTC Therapeutics (PTCT) Stock: Here’s What You Need To Know

PTC Therapeutics (NASDAQ:PTCT) On Monday, PTC Therapeutics fell by 40% to $7.97 per share after the company had announced that the FDA refused its appeal for a refuse-to-file letter. PTC Therapeutics has not been able to get the FDA to back its Duchenne Muscular Dystrophy — DMD — drug. What happened was that PTC had … Read more